Roche, GSK Face Compulsory Licensing Of Antivirals If Swine Flu Emergency Hits - South Korean Health Minister
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) could be manufactured under compulsory licensing in South Korea if the country faces an emergency swine flu threat in the coming months, Health, Welfare and Family Affairs Minister Jeon Jae-Hee said
You may also be interested in...
Korea To Bolster Fast-Track System With Speedier Approvals In Mind
With a broad ambition to improve the global competitiveness of its biopharma industry, South Korea is steadily unveiling supportive regulatory measures.
Korea To Bolster Fast-Track System With Speedier Approvals In Mind
With a broad ambition to improve the global competitiveness of its biopharma industry, South Korea is steadily unveiling supportive regulatory measures. Among the planned steps this year are the strengthening and clarification of an existing fast-track review and approval system, although the government says a limited number of reviewers may hamper the improved handling of such evaluations.
Korea Provides Tamiflu Government Stockpile To Roche
To help cope with the rising number of patients with A/H1N1, Korea handed over some of its government stockpile of Tamiflu supplies to Roche.